Cardio Diagnostics Holdings (CDIO) Share-based Compensation (2023 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Share-based Compensation of $24733.0 for Q1 2026, up 2.7% sequentially from $24083.0 in Q4 2025, and down 19.2% YoY from $30612.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Share-based Compensation (2023 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Share-based Compensation for 4 years, with the latest figure at $24733.0 in Q1 2026.
- Quarterly Share-based Compensation fell 19.2% year-over-year to $24733.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104356.0 (up 1.93% YoY) and the FY2025 annual result came in at $110235.0, down 95.75% from the prior year.
- Share-based Compensation advanced to $24733.0 in Q1 2026 per CDIO's latest filing, from $24083.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.5 million in Q1 2024 and troughed at $4000.0 in Q1 2023.
- A 4-year average of $308108.4 and a median of $26731.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 62885.1% in 2024, then sank 98.78% in 2025.
- Over 4 years, Share-based Compensation stood at $62000.0 in 2023, then plunged by 63.85% to $22415.0 in 2024, then gained by 7.44% to $24083.0 in 2025, then grew by 2.7% to $24733.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $24733.0, $24083.0, and $24762.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | 24,352.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24,352.00 |
| Jun 30, 2026 | 24,352.00 |
| Mar 31, 2026 | 24,733.00 |
| Mar 31, 2026 | 24,733.00 |
| Dec 31, 2025 | 24,083.00 |
| Dec 31, 2025 | 24,083.00 |
| Sep 30, 2025 | 24,762.00 |
| Sep 30, 2025 | 24,762.00 |
| Jun 30, 2025 | 30,778.00 |
| Jun 30, 2025 | 30,778.00 |
| Mar 31, 2025 | 30,612.00 |
| Mar 31, 2025 | 30,612.00 |
| Dec 31, 2024 | 22,415.00 |
| Dec 31, 2024 | 22,415.00 |
| Sep 30, 2024 | 22,618.00 |
| Sep 30, 2024 | 22,618.00 |
| Jun 30, 2024 | 26,731.00 |
| Jun 30, 2024 | 26,731.00 |
| Mar 31, 2024 | 2.52 Mn |
| Mar 31, 2024 | 2.52 Mn |